Let’s dig into the relative performance of Repligen (NASDAQ:RGEN) and its peers as we unravel the now-completed Q1 drug ...

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take ...